A focus on Lean Six Sigma manufacturing is instrumental to this company’s strategy for future growth and success.
Converting a former pharmaceutical plant into a contract development and manufacturing organization (CDMO) is not an easy task. Even though both companies are involved in pharmaceuticals, relaunching the firm after this type of transformation can still be a tricky business. In 2008 Catalyst Capital Group purchased a facility in the greater Toronto area with the goal of relaunching it as a CDMO. The acquisition brought Catalyst Capital an empty plant with a lot of capacity, talented scientists, and upside potential. Unfortunately, the plant did not contain any of the processes needed for biopharmaceutical production.
When Nick Green, president and CEO, joined that company two years later, which by then had become Therapure Biopharma, he found a company that was already a successful biologics manufacturer. He created a strategy to enable the company to grow as quickly as possible and embarked on a journey to bring in additional clients.